Bexil Investment Trust Azioni (OTC: BXSY)

Ultime notizie per Bexil Investment Trust (OTC:BXSY) Azioni

Bexil Investment Trust is a diversified, closed-ended management investment company. The fund's investment objective is to seek high current income with a secondary objective of capital appreciation. The fund seeks to invest in stocks of companies operating across diversified sectors. It mainly invests in dividend-paying stocks of companies across all capitalizations. The Fund seeks to achieve its objectives by investing, under normal circumstances, in income-generating equity securities, including dividend-paying common stocks, convertible securities, preferred stocks, securities of registered investment companies, exchange-traded funds organized as investment companies or otherwise, real estate investment trusts, depositary receipts, and other equity-related securities.

Bexil Investment Trust

<ul>
<li>Phase 2 (Actuate-1801 Part 3B) trial meets primary endpoint and demonstrates a clinically meaningful increase in median overall survival (10.1 months vs 7.2 months; log-rank p=0.01) in previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving elraglusib/GnP</li>
<li>Risk of death was reduced by 37% (HR=0.63) in patients treated with elraglusib/GnP</li>
<li>Data featured as an oral presentation at the ASCO Annual Meeting</li>
<li>Company plans to engage with FDA in the second half of 2025 to align on a path towards product registration</li>
<li>Company to host KOL event today at 6:30 pm CDT to discuss 1801 Part 3B results</li>
</ul>

News

ACTU

Reported Saturday, Actuate's Elraglusib Meets Primary Endpoint In Phase 2 mPDAC Trial, Extending Median Overall Survival To 10.1 Months And Cutting Risk Of Death By 37%

Macro Economic Events

Econ #s

Economics

Eurozone Manufacturing Purchasing Managers Index For May 49.4 Vs. 48.4 Est.; 49.0	Prior

Germany Manufacturing Purchasing Managers Index For May 48.3 Vs. 48.8 Est.; 48.4 Prior

France Manufacturing Purchasing Managers Index For May 49.8 Vs. 49.5 Est.; 48.7 Prior

CLEU

Reported Sunday, China Liberal Education To Be Suspended From Nasdaq June 3 After Failing To Address 20-F Filing Delinquency

GILD

Reported Sunday, Gilead's Kite Presents Real-World Data At ASCO 2025 Supporting Outpatient Use Of Yescarta For R/R Large B-Cell Lymphoma With Comparable Safety And Efficacy

<ul>
<li>First Pivotal Phase 3 Trial to Show Superiority of a TROP-2 Antibody-Drug Conjugate, Trodelvy, Plus Keytruda Versus Standard of Care in 1L Metastatic TNBC –</li>
<li>Early Trend in Improvement in Overall Survival Observed</li>
</ul>

Reported Saturday, Gilead's TROP-2 ADC Trodelvy, In Combination With Keytruda, Shows Clinically Meaningful Survival Gains And Fewer Adverse Event-Related Discontinuations In ASCENT-04

The CNN Money Fear and Greed index showed some decline in the overall market sentiment, while the index remained in the &#8220;Greed&#8221; zone on Friday.
U.S. stocks settled mixed on Friday, with the Dow Jones index gaining more than 50 points during the session after President Donald Trump accused China of &#8220;totally&#8221; breaching a tariff agreement, raising new fears over trade disputes.
Wall Street closed on a positive note last month, with the S&amp;P 500 gaining more than 6.2% in May and the Nasdaq jumping 9.6%. Both indices recorded their strongest months since November 2023. The Dow surged 3.9% for the month.
For the week, the S&amp;P 500 climbed, while the 30-stock Dow climbed 1.6%. The tech-laden Nasdaq, meanwhile, surged 2% last week.
Shares of Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) fell more than 2% on Friday after the company reported mixed financial results for the first quarter. Shares of Ulta Beauty Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) jumped around 12% after the company reported better-than-expected first-quarter financial results and raised guidance.
On the economic data front, the University of Michigan consumer sentiment was revised higher to 52.2 in May versus a preliminary reading of 50.8. The Chicago PMI declined to 40.5 in May versus 44.6 in the previous month.
Most sectors on the S&amp;P 500 closed on a negative note, with energy, consumer discretionary and information technology stocks recording the biggest losses on Friday. However, consumer staples and utilities stocks bucked the overall market trend, closing the session higher.
The Dow Jones closed higher by around 54 points to 42,270.07 on Friday. The S&amp;P 500 slipped 0.01% to 5,911.69, while the Nasdaq Composite declined 0.32% to 19,113.77 during Friday's session.
Investors are awaiting earnings results from The Campbell&#8217;s Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NASDAQ">CPB</a>), Science Applications International Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIC#NASDAQ">SAIC</a>) and Credo Technology Group Holding Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 61.5, the index remained in the &#8220;Greed&#8221; zone on Friday, versus a prior reading of 62.4.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/cannabis/25/05/45692676/wall-streets-most-accurate-analysts-spotlight-on-3-utilities-stocks-delivering-high-dividend-yields-8">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Utilities Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo courtesy: Shutterstock

Equities

CRDO

DELL

SAIC

ULTA

S&P 500 Records Gain For May: Investor Sentiment Declines, But Fear Index Remains In 'Greed' Zone

<ul>
<li>Rusfertide plus current standard of care more than doubled clinical response rates across high- and low-risk PV groups, significantly reducing phlebotomy eligibility compared to placebo plus current standard of care, which was the primary endpoint</li>
<li>All key secondary endpoints met with statistical significance, including a nearly three-fold reduction in the proportion of patients requiring phlebotomy and a four-fold improvement in hematocrit control in rusfertide arm compared to placebo arm, as well as improvements in patient-reported outcomes</li>
<li>No serious adverse events considered related to rusfertide were reported</li>
<li>Rusfertide has received Orphan Drug designation and Fast Track designation from the U.S. FDA</li>
</ul>

PTGX

Reported Sunday, Protagonist And Takeda Present 32-Week VERIFY Data: Rusfertide Significantly Reduces Phlebotomy, Improves Symptoms In Polycythemia Vera

With U.S. stock futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as follows:
<ul class="wp-block-list">
<li>Wall Street expects Campbell&#8217;s Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NASDAQ">CPB</a>) to report quarterly earnings at 66 cents per share on revenue of $2.43 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Campbell&#8217;s shares gained 0.6% to $34.24 in after-hours trading.</li>
<li>Analysts expect Science Applications International Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIC#NASDAQ">SAIC</a>) to post quarterly earnings at $2.13 per share on revenue of $1.87 billion. The company will release earnings before the markets open. SAIC shares rose 0.2% to $115.71 in after-hours trading.</li>
<li>Plus Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) posted a net loss of $17.4 million, or $1.19 per share, for the first quarter, versus a year-ago net loss of $3.3 million, or 75 cents per share. Plus Therapeutics shares jumped 34.2% to $0.3851 in the after-hours trading session.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul class="wp-block-list">
<li>Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) announced plans to acquire Blueprint Medicines Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) for $9.5 billion. Blueprint Medicines shares fell 1.7% to close at $101.35 on Friday.</li>
<li>Analysts expect Credo Technology Group Holding Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) to post quarterly earnings at 28 cents per share on revenue of $160.16 million after the closing bell. Credo Technology shares gained 0.6% to $61.30 in after-hours trading.</li>
</ul>
Check This Out:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/cannabis/25/05/45692676/wall-streets-most-accurate-analysts-spotlight-on-3-utilities-stocks-delivering-high-dividend-yields-8"> Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Utilities Stocks Delivering High-Dividend Yields</a></li>
</ul>
Photo via Shutterstock

Tech

BPMC

PSTV

Campbell's, SAIC And 3 Stocks To Watch Heading Into Monday

China has refuted U.S. President Donald Trump&#8216;s claims of breaching the Geneva trade agreement, labeling them as unfounded. 
What Happened: On Monday, China's Commerce Ministry rejected Trump's accusations that Beijing had breached the Geneva trade agreement. The ministry confirmed that China had implemented and consistently upheld the agreement reached in Geneva last month, <a href="https://english.news.cn/20250602/ebecebe8437e464da4723ebd20a5e72b/c.html">reported </a>Xinhua News.
The Chinese government stated that the U.S. had &#8220;groundlessly&#8221; accused the nation of breaching the trade deal and pledged to take aggressive measures to protect its interests.
Trump had accused China of breaching a bilateral deal to reduce tariffs. The ministry countered, stating that the U.S. had imposed several &#8220;discriminatory restrictive&#8221; measures against China, such as restricting AI chip exports, banning the sale of chip design software to China and revoking visas for Chinese students. 
&#8220;The U.S. government has unilaterally and repeatedly provoked new economic and trade frictions, exacerbating uncertainty and instability in bilateral economic and trade relations,&#8221; the ministry stated. 
SEE ALSO: <a href="https://benzinga.com/cannabis/25/05/45691518/110m-wiped-out-bitcoin-whale-trader-gets-burned-as-btc-tags-104150" target="_blank" rel="noreferrer noopener">$110M Wiped Out: Bitcoin Whale Trader Gets Burned As BTC Tags $104,150 &#8211; Benzinga</a>
Why It Matters: This recent dispute follows a series of events that have strained U.S.-China trade relations. On Friday, President Trump accused China of violating an agreement to ease tariffs. Analysts suggest China&#8217;s delay in approving rare earth export licenses, over which it holds strategic control, may have fueled Trump&#8217;s anger, even though he didn&#8217;t directly mention them in his accusations, reported the South China Morning Post.
Following the development. the U.S.-listed Chinese stocks, including Baidu, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) and Alibaba Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45703311/us-listed-chinese-stocks-drop-after-trump-renews-trade-tensions">dropped</a> 2.95% and 2.85%, respectively.
A day prior to that, China called on the U.S. to completely <a href="https://www.benzinga.com/markets/25/05/45664337/china-tells-us-to-entirely-revoke-wrongful-unilateral-tariffs-after-court-blocks-trumps-liberation-day-levies">withdraw </a>the unilateral tariff measures when a U.S. federal court blocked Trump tariffs which have now been temporarily reinstated.
Meanwhile, U.S. Treasury Secretary Scott Bessent indicated that trade negotiations between the two countries had reached a <a href="https://www.benzinga.com/25/05/45685544/scott-bessent-says-us-china-trade-talks-at-stalemate-need-trump-and-xi-jinping-touch-to-break-the-deadlock">stalemate</a>. On Sunday, Bessent stated in an interview with CBS news that he is confident President Trump and Chinese President Xi Jinping would meet &#8220;soon&#8221; and iron out the differences. 
<ul class="wp-block-list">
<li>READ MORE: <a href="https://benzinga.com/cannabis/25/06/45714198/elon-musks-kekius-maximus-gameplay-sends-these-namesake-coins-surging" target="_blank" rel="noreferrer noopener">Elon Musk&#8217;s &#8216;Kekius Maximus&#8217; Gameplay Sends These Namesake Coins Surging &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

BABA

BIDU

Xi Jinping's China Dismisses Trump's 'Groundless' Accusations On Geneva Trade Deal Breach, Vows Strong Retaliation

Scott Bessent, the U.S. Treasury Secretary, assured that the country will not default on its debt, even as the deadline for raising the federal debt ceiling approaches.
What Happened: Bessent, in an interview with CBS&#8217;s Face the Nation on Sunday, dismissed the possibility of a default. &#8220;The United States of America is never going to default. That is never going to happen,&#8221; he said, <a href="https://www.cbsnews.com/news/scott-bessent-treasury-secretary-face-the-nation-06-01-2025/">reported</a> CBS News.
The debt ceiling, a cap set by Congress on the amount of debt the federal government can legally borrow, is a contentious issue. Republican leaders have linked the debt limit increase to President&nbsp;Donald Trump&#8216;s tax and spending bill, adding complexity to the negotiations over the legislation.
Bessent did not reveal the &#8220;X date&#8221; — the moment when the Treasury exhausts its cash and special accounting maneuvers that help it remain under the debt ceiling while continuing to meet federal obligations on time. He explained that this information is used to advance the bill.
He also responded to a warning from Jamie Dimon, CEO of JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>), regarding a possible disruption in the bond market. Bessent said, &#8220;I've known Jamie for a long time, and for his entire career he's made predictions like this. Fortunately none of them have come true.&#8221; 
<path fill-rule="evenodd" clip-rule="evenodd" d="M7 5C7 3.34315 8.34315 2 10 2H19C20.6569 2 22 3.34315 22 5V14C22 15.6569 20.6569 17 19 17H17V19C17 20.6569 15.6569 22 14 22H5C3.34315 22 2 20.6569 2 19V10C2 8.34315 3.34315 7 5 7H7V5ZM9 7H14C15.6569 7 17 8.34315 17 10V15H19C19.5523 15 20 14.5523 20 14V5C20 4.44772 19.5523 4 19 4H10C9.44772 4 9 4.44772 9 5V7ZM5 9C4.44772 9 4 9.44772 4 10V19C4 19.5523 4.44772 20 5 20H14C14.5523 20 15 19.5523 15 19V10C15 9.44772 14.5523 9 14 9H5Z" fill="currentColor"></path>
<path fill-rule="evenodd" clip-rule="evenodd" d="M12.1318 2.50389C12.3321 2.15338 12.7235 1.95768 13.124 2.00775L13.5778 2.06447C16.0449 2.37286 17.636 4.83353 16.9048 7.20993L16.354 8.99999H17.0722C19.7097 8.99999 21.6253 11.5079 20.9313 14.0525L19.5677 19.0525C19.0931 20.7927 17.5124 22 15.7086 22H6C4.34315 22 3 20.6568 3 19V12C3 10.3431 4.34315 8.99999 6 8.99999H8C8.25952 8.99999 8.49914 8.86094 8.6279 8.63561L12.1318 2.50389ZM10 20H15.7086C16.6105 20 17.4008 19.3964 17.6381 18.5262L19.0018 13.5262C19.3488 12.2539 18.391 11 17.0722 11H15C14.6827 11 14.3841 10.8494 14.1956 10.5941C14.0071 10.3388 13.9509 10.0092 14.0442 9.70591L14.9932 6.62175C15.3384 5.49984 14.6484 4.34036 13.5319 4.08468L10.3644 9.62789C10.0522 10.1742 9.56691 10.5859 9 10.8098V19C9 19.5523 9.44772 20 10 20ZM7 11V19C7 19.3506 7.06015 19.6872 7.17071 20H6C5.44772 20 5 19.5523 5 19V12C5 11.4477 5.44772 11 6 11H7Z" fill="currentColor"></path>
<path fill-rule="evenodd" clip-rule="evenodd" d="M11.8727 21.4961C11.6725 21.8466 11.2811 22.0423 10.8805 21.9922L10.4267 21.9355C7.95958 21.6271 6.36855 19.1665 7.09975 16.7901L7.65054 15H6.93226C4.29476 15 2.37923 12.4921 3.0732 9.94753L4.43684 4.94753C4.91145 3.20728 6.49209 2 8.29589 2H18.0045C19.6614 2 21.0045 3.34315 21.0045 5V12C21.0045 13.6569 19.6614 15 18.0045 15H16.0045C15.745 15 15.5054 15.1391 15.3766 15.3644L11.8727 21.4961ZM14.0045 4H8.29589C7.39399 4 6.60367 4.60364 6.36637 5.47376L5.00273 10.4738C4.65574 11.746 5.61351 13 6.93226 13H9.00451C9.32185 13 9.62036 13.1506 9.8089 13.4059C9.99743 13.6612 10.0536 13.9908 9.96028 14.2941L9.01131 17.3782C8.6661 18.5002 9.35608 19.6596 10.4726 19.9153L13.6401 14.3721C13.9523 13.8258 14.4376 13.4141 15.0045 13.1902V5C15.0045 4.44772 14.5568 4 14.0045 4ZM17.0045 13V5C17.0045 4.64937 16.9444 4.31278 16.8338 4H18.0045C18.5568 4 19.0045 4.44772 19.0045 5V12C19.0045 12.5523 18.5568 13 18.0045 13H17.0045Z" fill="currentColor"></path>
<path d="M2.5 5.5C4.3 5.2 5.2 4 5.5 2.5C5.8 4 6.7 5.2 8.5 5.5C6.7 5.8 5.8 7 5.5 8.5C5.2 7 4.3 5.8 2.5 5.5Z" fill="currentColor" stroke="currentColor" stroke-linecap="round" stroke-linejoin="round"></path>
<path d="M5.66282 16.5231L5.18413 19.3952C5.12203 19.7678 5.09098 19.9541 5.14876 20.0888C5.19933 20.2067 5.29328 20.3007 5.41118 20.3512C5.54589 20.409 5.73218 20.378 6.10476 20.3159L8.97693 19.8372C9.72813 19.712 10.1037 19.6494 10.4542 19.521C10.7652 19.407 11.0608 19.2549 11.3343 19.068C11.6425 18.8575 11.9118 18.5882 12.4503 18.0497L20 10.5C21.3807 9.11929 21.3807 6.88071 20 5.5C18.6193 4.11929 16.3807 4.11929 15 5.5L7.45026 13.0497C6.91175 13.5882 6.6425 13.8575 6.43197 14.1657C6.24513 14.4392 6.09299 14.7348 5.97903 15.0458C5.85062 15.3963 5.78802 15.7719 5.66282 16.5231Z" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"></path>
<path d="M14.5 7L18.5 11" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"></path> 
<path d="M3.06957 10.8763C3.62331 6.43564 7.40967 3 12 3C14.2824 3 16.4028 3.85067 18.0118 5.25439V4C18.0118 3.44772 18.4595 3 19.0118 3C19.5641 3 20.0118 3.44772 20.0118 4V8C20.0118 8.55228 19.5641 9 19.0118 9H15C14.4477 9 14 8.55228 14 8C14 7.44772 14.4477 7 15 7H16.9571C15.6757 5.76379 13.9101 5 12 5C8.43108 5 5.48466 7.67174 5.0542 11.1237C4.98586 11.6718 4.48619 12.0607 3.93815 11.9923C3.39011 11.924 3.00123 11.4243 3.06957 10.8763ZM20.0618 12.0077C20.6099 12.076 20.9988 12.5757 20.9304 13.1237C20.3767 17.5644 16.5903 21 12 21C9.72322 21 7.60762 20.1535 5.99999 18.7559V20C5.99999 20.5523 5.55228 21 4.99999 21C4.44771 21 3.99999 20.5523 3.99999 20V16C3.99999 15.4477 4.44771 15 4.99999 15H8.99999C9.55228 15 9.99999 15.4477 9.99999 16C9.99999 16.5523 9.55228 17 8.99999 17H7.04285C8.32433 18.2362 10.0899 19 12 19C15.5689 19 18.5153 16.3283 18.9458 12.8763C19.0141 12.3282 19.5138 11.9393 20.0618 12.0077Z" fill="currentColor"></path>
<path fill-rule="evenodd" clip-rule="evenodd" d="M5.29289 9.29289C5.68342 8.90237 6.31658 8.90237 6.70711 9.29289L12 14.5858L17.2929 9.29289C17.6834 8.90237 18.3166 8.90237 18.7071 9.29289C19.0976 9.68342 19.0976 10.3166 18.7071 10.7071L12.7071 16.7071C12.5196 16.8946 12.2652 17 12 17C11.7348 17 11.4804 16.8946 11.2929 16.7071L5.29289 10.7071C4.90237 10.3166 4.90237 9.68342 5.29289 9.29289Z" fill="currentColor"></path>
SEE ALSO:&nbsp;<a href="https://benzinga.com/cannabis/25/06/45713593/trump-shares-baseless-theory-about-bidens-alleged-execution-and-subsequent-robotic-replacement-in-2020" target="_blank" rel="noreferrer noopener">Trump Shares Baseless Theory About Biden&#8217;s Alleged Execution And Subsequent Robotic Replacement In 2020</a>
Why It Matters: The assurance from Bessent comes amid warnings from financial experts.&nbsp;<a href="https://www.benzinga.com/markets/economic-data/25/05/45704089/jamie-dimon-warns-of-bond-market-crisis-caused-by-us-debt-binge-youre-going-to-panic">Jamie Dimon</a> had recently warned of a potential crisis in the bond market due to unchecked debt and monetary expansion. Similarly, former Treasury Secretary&nbsp;<a href="https://www.benzinga.com/markets/25/05/45686699/larry-summers-issues-stark-warning-the-big-beautiful-bill-is-actually-a-prescription-for-deadly-dangerous-decline">Larry Summers</a>&nbsp;had criticized the lack of fiscal discipline in current Republican proposals, warning of a potential crisis if current debt trends continue. 
The statements from Bessent are crucial in maintaining investor confidence amid these criticisms. 
Meanwhile, the Treasury Secretary also ruled out apprehensions about inflation. "Actually, the inflation numbers are the best in four years. So why don't we stop trying to say this could happen, and wait and see what does happen,&#8221; stated Bessent.
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/cannabis/25/06/45713578/jerome-powell-to-step-down-x-abuzz-with-rumors-but-polymarket-bettors-are-not-buying-it" target="_blank" rel="noreferrer noopener">Jerome Powell To Step Down? X Abuzz With Rumors, But Polymarket Bettors Are Not Buying It &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

US 'Never Going To Default,' Says Scott Bessent, Dismissing Jamie Dimon's Debt Crisis Warnings: 'For His Entire Career…'

Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) Co-Founder Joe Lonsdale delivered sharp criticism of America&#8217;s healthcare system during the Reagan National Economic Forum, calling for artificial intelligence adoption and regulatory reform to combat rising costs and China&#8217;s growing biotechnology dominance.
What Happened: Speaking on CNBC, Lonsdale outlined a two-pronged crisis threatening U.S. healthcare leadership. On the biotechnology front, China has captured 30% of the global biotech market in just five years, leveraging regulatory speed advantages to undercut American innovation. 
&#8220;They take a company we started a year or two ago, go after the same target, get through their regulators faster and then sell it back to our pharma companies,&#8221; Lonsdale said, citing the FDA&#8217;s decade-long approval timelines as a critical competitive disadvantage.
The venture capitalist emphasized that China&#8217;s biotechnology surge combines legitimate innovation with intellectual property theft. This dynamic discourages U.S. investment in certain therapeutic areas where regulatory delays create vulnerability to foreign competition.
See Also: <a href="https://www.benzinga.com/markets/market-summary/25/06/45713715/dow-futures-slip-over-100-points-after-trump-announces-doubling-steel-tariffs-nikkei-down" target="_blank" rel="noreferrer noopener">Dow Futures Slip Over 100 Points After Trump Announces Doubling Steel Tariffs, Nikkei Down</a>
Why It Matters: Healthcare services represent the second battleground, with Lonsdale describing city-based hospital systems as &#8220;effectively cartels&#8221; that block competition through state-level legislation. These barriers prevent new provider networks and limit patient data portability, driving up costs across the healthcare economy.
Current healthcare inflation threatens national fiscal stability, with unfunded Medicare and Medicaid obligations. &#8220;If that keeps going up 6-7% a year, no one&#8217;s going to get healthcare except for maybe the rich,&#8221; Lonsdale warned, noting healthcare&#8217;s resistance to broader deflationary trends.
Lonsdale praised Elon Musk&#8217;s Department of Government Efficiency (DOGE) efforts, noting the program cut approximately $150-160 billion annually before Musk&#8217;s departure. He calculated that this represents $3 trillion in equity value based on the government&#8217;s cost of capital. 
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Palantir Co-Founder Joe Lonsdale on the growing important of AI in defense" width="500" height="281" src="https://www.youtube.com/embed/3zlOYet-cqA?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/cannabis/25/06/45713895/bitcoin-ethereum-dogecoin-hold-steady-amid-us-china-trade-war-tensions-analyst-foresees-big-party-if-btc-reclaims-106000" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum, Dogecoin Hold Steady Amid US-China Trade War Tensions: Analyst Foresees ‘Big Party' If BTC Reclaims $106,000</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo Courtesy: PeopleImages.com &#8211; Yuri A On Shutterstock.com

Health Care

PLTR

Joe Lonsdale Slams Healthcare 'Cartels:' Urges AI, Regulatory Reform To Slash Costs, Reclaim Biotech From China

Highlights of the REZILIENT1 Phase 1/2 trial in the authors' conclusions include:
<ul>
<li>Zipalertinib demonstrated clinically meaningful efficacy in the primary efficacy population (n=176), including 51 patients who had received prior amivantamab.</li>
<li>The confirmed objective response rate (ORR) was 35.2% overall, and median duration of response (mDOR) and progression-free survival were 8.8 months and 9.4 months, respectively.</li>
<li>In patients treated after prior platinum-based chemotherapy only (n=125), ORR was 40% with mDOR of 8.8 months.</li>
<li>The safety profile of zipalertinib was manageable and consistent with previously reported data.¹</li>
<li>In exploratory subgroup analyses:
<ul>
<li>Patients who had received prior&nbsp;amivantamab without other ex20ins-targeted therapy showed a confirmed ORR of 30% and mDOR of 14.7 months.</li>
<li>Patients with brain metastases showed a confirmed&nbsp;ORR of 30.9% and a mDOR of 8.3 months</li>
</ul>
</li>
</ul>

CGEM

TAIHF

Reported Sunday, Taiho And Cullinan's Zipalertinib Shows 40% ORR In Platinum-Treated EGFR ex20ins NSCLC, REZILIENT1 Results Published In JCO

Reported Saturday, Tempus Unveils Fuses Program To Transform Precision Medicine With AI-Powered Diagnostic Models And Multimodal Data At Scale

<ul>
<li>TROPION-Lung02 and TROPION-Lung04 phase 1b results support combination of Daiichi Sankyo and AstraZeneca's DATROWAY with immunotherapy as first-line treatment for advanced or metastatic NSCLC</li>
<li>TROPION-Lung02 results include first exploratory QCS analysis of DATROWAY in first-line setting</li>
<li>NeoCOAST-2 phase 2 results continue to show potential for DATROWAY plus durvalumab and single-agent platinum chemotherapy in neoadjuvant setting</li>
</ul>

DSNKY

Reported Sunday, AstraZeneca's DATROWAY Shows Over 55% Response Rate In First-Line Advanced NSCLC In TROPION-Lung02 Phase 1b Trial With Immunotherapy Combinations

<ul>
<li>Two-thirds (67.4%) of patients treated with IMFINZI-based perioperative regimen remained event-free at two years</li>
<li>First and only immunotherapy to demonstrate statistically significant event-free survival in a global Phase III trial in this setting</li>
</ul>

Reported Sunday, AstraZeneca's IMFINZI Regimen Reduces Risk Of Progression, Recurrence, Or Death By 29% In Early Gastric Cancer In Phase 3 MATTERHORN Trial

First pivotal trial to demonstrate clinical value of monitoring circulating tumor DNA to detect and treat emerging resistance in 1st-line therapy ahead of disease progression in breast cancer
First and only next-generation oral SERD and complete ER antagonist to demonstrate consistent progression-free survival benefit in combination with widely approved CDK4/6 inhibitors in 1st-line advanced breast cancer

Reported Sunday, AstraZeneca's Camizestrant Reduces Risk Of Progression Or Death By 56% In HR+ Advanced Breast Cancer With ESR1 Mutation In SERENA-6 Trial

Campbell's Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NASDAQ">CPB</a>) will release its third-quarter earnings results before the opening bell on <a href="https://www.benzinga.com/quote/cpb/earnings">Monday, June 2.</a>
Analysts expect the Camden, New Jersey-based company to report quarterly earnings at 66 cents per share, down from 75 cents per share in the year-ago period. Campbell's projects to report quarterly revenue of $2.43 billion. Compare that to the $2.37 billion it reported last year, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On March 5, the company reported second-quarter sales growth of 9% to $2.685 billion, missing the analyst consensus estimate of $2.74 billion.
Campbell's shares fell 0.4% to close at $34.04 on Friday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/cpb/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>Wells Fargo analyst Chris Carey maintained an Equal-Weight rating and slashed the price target from $40 to $34 on May 30, 2025. This analyst has an accuracy rate of 63%.</li>
<li>Piper Sandler analyst Michael Lavery maintained an Overweight rating and cut the price target from $45 to $42 on May 23, 2025. This analyst has an accuracy rate of 66%.</li>
<li>Morgan Stanley analyst Megan Alexander initiated coverage on the stock with an Equal-Weight rating and a price target of $40 on March 24, 2025. This analyst has an accuracy rate of 70%.</li>
<li>JP Morgan analyst Ken Goldman downgraded the stock from Overweight to Neutral and cut the price target from $48 to $37 on March 6, 2025. This analyst has an accuracy rate of 78%.</li>
<li>Jefferies analyst Rob Dickerson maintained a Hold rating and slashed the price target from $42 to $40 on March 5, 2025. This analyst has an accuracy rate of 66%</li>
</ul>
Considering buying CPB stock? Here&#8217;s what analysts think:
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/cannabis/25/05/45692676/wall-streets-most-accurate-analysts-spotlight-on-3-utilities-stocks-delivering-high-dividend-yields-8">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Utilities Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Earnings

Price Target

Pre-Market Outlook

Analyst Ratings

Trading Ideas

Top Wall Street Forecasters Revamp Campbell's Expectations Ahead Of Q3 Earnings

<ul>
<li>Daiichi Sankyo and AstraZeneca's ENHERTU demonstrated a median overall survival of 14.7 months</li>
<li>Results reinforce second-line use of ENHERTU globally in this setting</li>
</ul>

Reported Saturday, Daiichi Sankyo And AstraZeneca's ENHERTU Demonstrates 14.7-Month Median OS And 30% Reduction In Risk Of Death In HER2+ Gastric Cancer

Comments

Bexil Investment Trust

Notizie

Ultime notizie per Bexil Investment Trust (OTC:BXSY) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO